184 related articles for article (PubMed ID: 23451862)
1. Canakinumab in pediatric rheumatic diseases.
Wulffraat NM; Woo P
Expert Opin Biol Ther; 2013 Apr; 13(4):615-22. PubMed ID: 23451862
[TBL] [Abstract][Full Text] [Related]
2. [Canakinumab: a promising treatment in rheumatology].
Fabreguet I; So A
Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
[TBL] [Abstract][Full Text] [Related]
3. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
Orrock JE; Ilowite NT
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
[TBL] [Abstract][Full Text] [Related]
4. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
5. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.
Bettiol A; Lopalco G; Emmi G; Cantarini L; Urban ML; Vitale A; Denora N; Lopalco A; Cutrignelli A; Lopedota A; Venerito V; Fornaro M; Vannacci A; Rigante D; Cimaz R; Iannone F
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999610
[TBL] [Abstract][Full Text] [Related]
6. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
[TBL] [Abstract][Full Text] [Related]
7. Canakinumab.
Dhimolea E
MAbs; 2010; 2(1):3-13. PubMed ID: 20065636
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome".
Yokota S; Kikuchi M; Nozawa T; Kanetaka T; Sato T; Yamazaki K; Sakurai N; Hara R; Mori M
Mod Rheumatol; 2015 Jan; 25(1):1-10. PubMed ID: 24842480
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
Chakraborty A; Tannenbaum S; Rordorf C; Lowe PJ; Floch D; Gram H; Roy S
Clin Pharmacokinet; 2012 Jun; 51(6):e1-18. PubMed ID: 22550964
[TBL] [Abstract][Full Text] [Related]
10. Canakinumab for the treatment of systemic juvenile idiopathic arthritis.
Grom AA
Expert Rev Clin Immunol; 2014 Nov; 10(11):1427-35. PubMed ID: 25269376
[TBL] [Abstract][Full Text] [Related]
11. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
Walsh GM
Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
[TBL] [Abstract][Full Text] [Related]
13. Canakinumab for the treatment of adult-onset Still's disease.
Sfriso P; Bindoli S; Doria A; Feist E; Galozzi P
Expert Rev Clin Immunol; 2020 Feb; 16(2):129-138. PubMed ID: 31957508
[No Abstract] [Full Text] [Related]
14. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
Curran MP
BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
[TBL] [Abstract][Full Text] [Related]
15. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
[TBL] [Abstract][Full Text] [Related]
16. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
18. Treating inflammation by blocking interleukin-1 in humans.
Dinarello CA; van der Meer JW
Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
[TBL] [Abstract][Full Text] [Related]
19. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
Feist E; Burmester GR
Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
[TBL] [Abstract][Full Text] [Related]
20. Cryopyrin-associated periodic syndromes: diagnosis and management.
Miyamae T
Paediatr Drugs; 2012 Apr; 14(2):109-17. PubMed ID: 22335455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]